Is VBI Vaccines Inc.’s (NASDAQ:VBIV) Stock On The Decline?

The trading price of VBI Vaccines Inc. (NASDAQ:VBIV) floating lower at last check on Tuesday, April 02, closing at $0.59, -4.19% lower than its previous close.

In examining the 52-week price action we see that the stock hit a 52-week high of $9.54 and a 52-week low of $0.45. Over the past month, the stock has gained 0.37% in value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

VBI Vaccines Inc., whose market valuation is $14.03 million at the time of this writing, is expected to release its quarterly earnings report Apr 02, 2024 – Apr 06, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.22 per share this quarter, however they have predicted annual earnings per share of -$6.59 for 2023 and -$0.82 for 2024. It means analysts are expecting annual earnings per share growth of -1,397.70% this year and 87.60% next year.

Analysts have forecast the company to bring in revenue of $5.36 million for the current quarter, with the likely lows of $5.36 million and highs of $5.36 million. The average estimate suggests sales will likely up by 1,729.40% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $13.19 million. The company’s revenue is forecast to grow by 1,119.00% over what it did in 2023.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of VBI Vaccines Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest VBIV has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.

A quick review shows that VBIV’s price is currently 1.41% off the SMA20 and -3.16% off the SMA50. The RSI metric on the 14-day chart is currently showing 50.28, and weekly volatility stands at 4.36%. When measured over the past 30 days, the indicator reaches 5.62%. VBI Vaccines Inc. (NASDAQ:VBIV)’s beta value is currently sitting at 1.91, while the Average True Range indicator is currently displaying 0.04.

To see how VBI Vaccines Inc. stock has been performing today in comparison to its peers in the industry, here are the numbers: VBIV stock’s performance was -4.19% at last check in today’s session, and -93.73% in the past year.

An evaluation of the daily trading volume of VBI Vaccines Inc. (NASDAQ:VBIV) indicates that the 3-month average is 124.18K. However, this figure has increased over the past 10 days to an average of 78360.0.

Currently, records show that 23.69 million of the company’s shares remain outstanding. The insiders hold 5.94% of outstanding shares, whereas institutions hold 12.26%. The stats also highlight that short interest as of Mar 15, 2024, stood at 0.3 million shares, resulting in a short ratio of 1.81 at that time. From this, we can conclude that short interest is 1.28% of the company’s total outstanding shares. It is noteworthy that short shares in March were down slightly from the previous month’s figure, which was 0.37 million. However, since the stock’s price has seen 0.80% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.